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Abstract
Droplet digital polymerase chain reaction (ddPCR) is a highly sensitive and accurate method for quantification of
nucleic acid sequences. We used absolute quantification of mutated v-Ki-ras2 Kirsten rat sarcoma viral oncogene
homology gene (KRAS) by ddPCR to investigate the prognostic role of mutated KRAS in patients with KRAS-
mutated lung adenocarcinomas. Pre-treatment plasma samples from 60 patients with stages I–IV KRAS-mutated
lung adenocarcinomas were analysed for KRAS mutations. The associations between survival, detectable KRAS
mutations in plasma, and the plasma concentration of mutated KRAS were assessed. Overall, 23 of 60 (38%)
patients had detectable KRAS mutation in plasma. The percentage of patients with detectable mutation was 8%
in stage I, 30% in stage II, 71% in stage III, and 73% in stage IV. Estimated overall median progression-free sur-
vival (PFS) and overall survival (OS) were 26.2 months [95% confidence interval (CI) 12.5–39.9] and
50.8 months (95% CI 0–107.3), respectively. Patients with detectable mutations in plasma had significantly
worse median PFS compared to patients with undetectable mutation (13.1 versus 70.1 months) and shorter
median OS (20.7 versus not reached). High circulating tumour DNA (ctDNA) concentrations of mutated KRAS
were significantly associated with shorter PFS [hazard ratio (HR) 1.008, 95% CI 1.004–1.012] and OS
(HR 1.007, 95% CI 1.003–1.011). All associations remained statistically significant in multivariable analyses. In
conclusion, ddPCR is an accurate and easily feasible technique for quantification of KRAS mutations in ctDNA.
The presence of detectable KRAS mutation in plasma at baseline was associated with worse PFS and OS. High
concentration of mutated KRAS in ctDNA was an independent negative prognostic factor for both PFS and OS.
Keywords: non-small cell lung cancer; liquid biopsy; plasma analyses; droplet digital PCR; ctDNA levels
Received 13 October 2020; Revised 21 December 2020; Accepted 4 January 2021
No conflicts of interest were declared.
Introduction
Despite recent advances in the treatment of non-small
cell lung cancer (NSCLC) with the introduction of tyro-
sine kinase inhibitors and immune checkpoint inhibitors,
lung cancer is still the leading cause of death worldwide.
Next-generation sequencing (NGS) technologies have
become widely accessible and have improved the knowl-
edge of druggable genetic aberrations in tumour DNA, as
well as genetic aberrations interfering with targeted treat-
ment strategies. However, there is still a need for easily
assessable biomarkers that can be used for better prog-
nostication of individual patients. Analyses of circulating
cell-free DNA (cfDNA) and circulating tumour DNA
(ctDNA) are promising approaches. cfDNA comprises
DNA released from non-malignant cells and a smaller
ctDNA fraction derived from apoptotic and necrotic
tumour cells [1] and possibly by active release from
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tumour cells [2]. ctDNA may include information from
genetically heterogenous areas of the primary tumour and
metastatic sites, possibly reflecting the whole tumour
genome [3]. ctDNA analyses have a growing number of
clinical applications. In lung adenocarcinoma patients,
ctDNA analyses for the detection of druggable genetic
aberrations, or mutations associated with treatment resis-
tance mechanisms, have become an important alternative
when tissue is not available for analysis [4–9]. Studies also
indicate that detectable ctDNA and high pre-treatment
ctDNA concentrations are associated with a negative
impact on survival in various cancer types [10–13].
Detectable ctDNA after treatment for localised cancer may
predict recurrence [14], while an increase in ctDNA con-
centration during follow-up may indicate relapse or pro-
gression, enabling disease monitoring and detection of
progression in advance of image detection [15–17].
Hot-spot mutations in codons 12 and 13 in exon 2 of
the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homol-
ogy gene (KRAS) are the most common driver mutations
in lung adenocarcinomas and are found in approximately
25–30% of non-Asian patients [18,19]. Thus, we consid-
ered KRAS a relevant biomarker for investigating the
prognostic role of ctDNA in patients with lung adenocar-
cinomas harbouring KRAS mutations. Using droplet digi-
tal polymerase chain reaction (ddPCR) technology for
accurate quantification of mutated KRAS, we aimed to
explore whether there was a difference in progression-
free survival (PFS) and overall survival (OS) between
patients with and without detectable KRAS mutations in
plasma at baseline. We also explored whether there was
an association between the plasma concentration of
mutated KRAS and PFS and OS.
Materials and methods
Ethics
This study was approved by the Regional Committee
for Medical and Health Research Ethics (REC) in Cen-
tral Norway. Both tissue and plasma samples were col-
lected from Biobank1®, the regional research biobank
in Central Norway. The biobank is approved by the
REC in Central Norway, the Ministry of Health and
Care Services, and the Norwegian Data Protection
Authority. Patients enrolled in the biobank are over
18 years old and have given written informed consent.
Patient inclusion and tumour specimens
A total of 553 patients with NSCLC were included in
the biobank from 2007 to 2018. All tumour specimens
in the biobank were reviewed and classified according
to the World Health Organization (WHO) 2015 classifi-
cation of lung tumours [20] by two lung pathologists
(SGFW and VGD). Clinical and pathological disease
stages were restaged according to the Eighth Edition of
the TNM Classification for lung cancer. Patients fulfill-
ing the following criteria were included: treatment-
naïve KRAS-mutated lung adenocarcinoma, available
blood sample collected prior to first treatment, and a
time interval of ≥5 years between the final control of
any previous cancer and the lung cancer. Sixty patients
fulfilled all criteria and were eligible for this study
(Figure 1). Clinicopathological baseline characteristics
were collected from the hospital medical records.
Tumour specimens were tested for KRAS mutations
using either the KRAS mutation analysis protocol
implemented for routine diagnostics at the Department
of Pathology, St. Olavs Hospital, or targeted NGS
using the Trusight Tumour 26 panel (Illumina®, San
Diego, CA, USA).
Blood samples and DNA extraction from plasma
A total of 10–18 ml peripheral whole blood was collected
in ethylenediaminetetraacetic (EDTA) acid tubes. Plasma
was prepared within 1 h by centrifugation at 4 C, either
at 2500 × g for 10 min or at 1500 × g for 15 min. Sam-
ples collected after 2016 had a second centrifugation step
at 10 000 × g for 10 min at 4 C. The plasma samples
were then aliquoted, transferred to cryotubes (Nalgene™
Cryotubes, Thermo Scientific™; Thermo Fisher Scientific
Inc., Waltham, MA, USA), and stored at −80 C until
DNA extraction. The plasma samples were thawed at
room temperature. cfDNA was extracted from 2 to 4 ml
plasma using the QIAamp® Circulating Nucleic Acid Kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s manual and was finally eluted in 50 μl of elution
buffer. The DNA concentration was quantified by a Qubit
fluorometer (Thermo Fisher Scientific Inc.).
Plasma samples used as KRAS mutation-negative
controls were prepared according to the same protocol
from deidentified healthy donor blood obtained from
the Department of Immunology and Transfusion Medi-
cine at St. Olavs Hospital and from patients included
in the biobank.
Validation of ddPCR assays
Before running the patient samples, we performed
mutation serial dilutions for each assay to test the ability
to detect and quantify specific mutant alleles in a back-
ground of excess wild-type (wt) DNA. Mutated KRAS
plasmid templates were serially diluted to 1:2 from a
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stock solution of 250 copies/μl down to 2 copies/μl for
all target KRAS mutations and further down to 0.5 cop-
ies/μl for KRAS G12A. A 2-μl plasmid solution was
spiked into a background of 4 ng of genomic wt DNA
(approximately 1212 copies) extracted from blood sam-
ples from healthy individuals. The plasmid titre samples
and PCR reagents were loaded onto the QX200 Droplet
Digital PCR System (Bio-Rad Laboratories Inc., Hercules,
CA, USA) in triplicate or quadruplicate. In addition to
each serial dilution assay, we ran the following controls:
KRAS wt reference standards (Horizon Discovery, Cam-
bridge, UK) for assessment of assay performance; wt
genomic DNA controls extracted from blood samples
from healthy individuals (the same DNA used in the
KRAS plasmid dilutions) for the detection of false-
positive mutant KRAS; and DNA-free, non-template
controls (NTCs) for contamination. The PCR and data
analyses were performed as described for the KRAS
analyses of plasma samples. The wt reference standards,
NTCs, and cfDNA from healthy donors were used as
controls when running the patient samples. The wt
genomic DNA from healthy donors was also used as a
control in some of the set-ups. The performance of the
ddPCR assays was investigated using regression analy-
sis to assess the linearity of the serial dilutions.
For determination of the limit of detection (LOD), the
distribution of false-positive mutant KRAS copies in the
wt standards and wt controls per reaction for each assay
in both the mutation titration series and patient sample
set-ups was recorded. A 95% confidence interval
(CI) for false positives per assay was calculated, and the
upper limit of the CI was defined as the LOD.
KRAS analysis of plasma
KRAS analysis of plasma DNA was performed using
the QX200 Droplet Digital PCR System and Bio-
Rad’s ddPCR KRAS mutation assays (Bio-Rad Labo-
ratories). In brief, 5 μl of plasma DNA (2–30 ng) was
mixed in a total reaction volume of 20 μl with ddPCR
Supermix and primers and Taqman probes (Bio-Rad
Laboratories) for both wt and mutated KRAS alleles
Figure 1. Outline of patient selection. NOS, not otherwise specified.
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(p.G12D, p.G12A, p.G12V, p.G12C, p.G12S, and
p.G13D). The reaction mixture was partitioned into
aqueous droplets in oil by the QX200 Droplet Genera-
tor and then transferred to a PCR plate. The PCR was
carried out with a two-step thermal cycling protocol:
10 min at 95 C, 40 cycles of 30 s at 94 C and 60 s
at 56 C, and 10 min at 96 C. The reaction was held
at 4 C until the plate was transferred to the Bio-Rad’s
QX200 Droplet Reader to determine the level of fluo-
rescence in each droplet. The data were processed and
analysed using QuantaSoft version 1.74 software (Bio-
Rad Laboratories). The number of mutated and wt
KRAS-positive droplets was converted to the copy
number/μl of PCR reaction mixture by the software,
and the concentrations of mutated and wt KRAS
copies/ml plasma were then calculated. Three or four
replicas of each patient sample were run in each exper-
imental set-up. In addition, each set-up also included a
mutation-positive control, a mutation-negative control,
and an NTC. Plasmid DNA containing fragments of
the KRAS exon 2 target mutations or DNA isolated
from KRAS mutation-positive tumour samples was
used as the mutation-positive control. As mutation-
negative controls, either cfDNA from healthy blood
donors or KRAS wt reference standards (Horizon)
were used.
Statistics
Chi-square test for independence was used to explore
the association between the fraction of patients with
detectable KRAS and clinical stage. The independent-
samples t-test was used to compare the DNA yield from
plasma between patients with and without detectable
KRAS mutations in plasma. The Kruskal–Wallis H-test
was used to compare the DNA yield from plasma, and
the plasma concentration of mutated KRAS, across dis-
ease stages. PFS was defined as the time from diagnosis
until objective progression or death by any cause, and
OS was defined as the time from diagnosis until death
by any cause. Using the reversed Kaplan–Meier
method, median follow-up time for PFS and OS was
calculated for event-free patients from the date of diag-
nosis to the date the collection of survival data was
completed (July 2019). Survival was estimated using
the Kaplan–Meier method and compared using the log-
rank test. The Cox proportional hazard model was used
for multivariable analyses, adjusting for the following
baseline characteristics: age, sex, disease stage, WHO
performance status (PS), and treatment. The signifi-
cance level was defined as a two-sided p < 0.05. All
analyses were performed using the IBM SPSS Statistics




An overview of patient characteristics is presented in
Table 1. Median age was 69 (range 47–83) years; all
patients were former or current smokers; 37 (62%) were
women; and 25 (42%) had stage I disease, 10 (17%)
stage II, 14 (23%) stage III, and 11 (18%) had stage IV
disease. Thirty-three patients (55%) had WHO PS
0, 23 (38%) PS 1, and 4 (7%) PS 2. The primary treat-
ment was surgery in 42 patients (70%), curative
chemoradiotherapy in 3 (5%), and palliative treatment
in 15 (25%). Of the latter, 12 (80%) received platinum-
doublet chemotherapy, 1 (7%) received whole-brain
radiotherapy only, and 2 (13%) received palliative
radiotherapy. The distribution of KRAS mutations was
as follows: G12C in 31 (52%) patients, G12V in
13 (22%), G12D in 9 (15%), G12A in 3 (5%), G12S in
2 (3%), and G13D in 2 (3%) patients. Detailed clinical
data and tumour characteristics are listed in supplemen-
tary material, Table S1.
Assay validation and determination of detection
limits
Regression analyses revealed good linearity over the
range of dilutions with the following R2 values:
0.9957 for G12V, 0.9906 for G12C, 0.9963 for G12D,
0.9979 for G12S, 0.9884 for G12A, and 0.9933 for
G13D (see supplementary material, Figure S1). The
average number of false-positive mutated KRAS copies
detected per reaction was 0 for G12V, 0.0326 for
G12C, 0.392 for G12D, 0.093 for G12S, 0 for G12A,
and 0.063 for G13D. The upper limit of the 95% CI
for each assay was defined as the LOD and was as fol-
lows: 0 for G12V and G12A, 0.69 mutated copies for
G12D, 0 for G12A, 0.10 mutated copies for G12C,
0.29 mutated copies for G12S, and 0.19 mutated cop-
ies for G13D.
Plasma
The plasma samples were obtained as part of the pri-
mary investigation, with a median of 19 (range 0–307)
days prior to first treatment. In 38 patients, the plasma
samples were collected <38 days before first treatment;
in 18 patients, between 30 and 89 days before first
treatment; and in 4 patients, >90 days prior to first
treatment (see supplementary material, Table S1). The
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median cfDNA yield from plasma was 1.04 (range
0.40–6.24) ng/μl for disease stage I, 0.93 (range
0.46–5.03) ng/μl for stage II, 0.75 (range 0.40–1.58)
ng/μl for stage III, and 0.76 (range 0.37–1.28) ng/μl
for stage IV. There was no difference in the cfDNA
yield across the disease stages (p = 0.119). The
median DNA yield in patients with detectable KRAS
mutations in plasma was 0.89 (range 0.41–2.04) ng/μl
and 0.90 (range 0.37–0.6.24) ng/μl in patients with
non-detectable KRAS mutation. The difference in
DNA yield between these groups was not significant
(p = 0.67). Overall, 23 of 60 (38%) patients had
detectable KRAS mutation in plasma. The proportion
of patients with detectable KRAS mutation in plasma
increased significantly with increasing disease stage:
in stage I, 2 of 25 (8%) had detectable mutation; in
stage II, 3 of 10 (30%); in stage III, 10 of 14 (71%),
and in stage IV, 8 of 11 (73%) (p < 0.001). The con-
centration of mutated KRAS increased significantly
with disease stage, with a median of 0 (range 0–3.3)
copies/ml for stage I, 0 (range 0–92.4) for stage II,
11.26 (range 0–217.8) for stage III, and 84.1 (range
0–1208.0) for stage IV (p < 0.001). Within the group
of patients with detectable mutations, the median con-
centration was 37.0 (range 1.1–1208) mutated KRAS
copies/ml plasma. Results of the ctDNA analyses are
summarised in supplementary material, Table S1.
Progression-free and overall survival
The median follow up for PFS was 38.7 (range
9.44–115.5) months; 27 patients were alive and pro-
gression free when the data collection was completed.
The median follow-up for OS was 40.9 (range
9.4–142.0) months; 32 patients were alive at the time
of data collection completion.
For all patients, the estimated median PFS was
26.2 months (95% CI 12.5–39.9), and the estimated
Table 1. Baseline characteristics.
Characteristic Total (N = 60)
KRAS mutation status in plasma
Not detected (n = 37) Detected (n = 23)
Age 69 (47–83) 71 (54–79) 64 (47–83)
Sex
Female 37 (62) 21 (57) 16 (70)
Male 23 (38) 16 (43) 7 (30)
Smoking history
Non-smoker 0 (0) 0 (0) 0 (0)
Smoker/former smoker 60 (100) 37 (100) 23 (100)
WHO performance status
0 33 (55) 22 (60) 11 (48)
1 23 (38) 12 (32) 11 (48)
2 4 (7) 3 (8) 1 (4)
Clinical disease stage
IA 17 (28) 15 (41) 2 (9)
IB 8 (13) 8 (22) 0 (0)
IIA 4 (7) 2 (5) 2 (9)
IIB 6 (10) 5 (14) 1 (4)
IIIA 9 (15) 3 (8) 6 (26)
IIIB 5 (8) 1 (3) 4 (17)
IVA 8 (13) 2 (5) 6 (26)
IVB 3 (5) 1 (3) 2 (9)
Histology
Adenocarcinoma 60 (100) 37 (62) 23 (38)
Therapy
Complete resection 42 (70) 32 (87) 10 (44)
Curative chemoradiotherapy 3 (5) 0 (0) 3 (13)
Palliative 15 (25) 5 (14) 10 (44)
KRAS mutation
G12C 31 (52) 19 (51) 12 (52)
G12V 13 (22) 7 (19) 6 (26)
G12D 9 (15) 7 (19) 2 (9)
G12S 2 (3) 1 (3) 1 (4)
G12A 3 (5) 2 (5) 1 (4)
G13D 2 (3) 1 (3) 1 (4)
Data are presented as median (range) or n (%).
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median OS was 50.8 months (95% CI 0–107.3).
Patients with detectable plasma KRAS mutations had
significantly worse median PFS compared with the
patients with non-detectable KRAS mutation (13.1 ver-
sus 70.1 months, p < 0.001) and significantly shorter
median OS (20.7 versus not reached, p = 0.002) (Fig-
ure 2). These associations remained statistically signif-
icant in the multivariable analyses, adjusting for
baseline characteristics for both PFS [hazard ratio
(HR) 2.76, 95% CI 1.064–7.162, p = 0.037] and OS
(HR 3.609, 95% CI 1.261–10.328, p = 0.017).
The concentration of mutated KRAS was signifi-
cantly associated with both shorter PFS (HR 1.008,
95% CI 1.004–1.012, p < 0.001) and OS (HR 1.007,
95% CI 1.003–1.011, p = 0.001). The associations
remained statistically significant in the multivariable
analyses (Table 2) for both PFS (HR 1.008, 95% CI
1.002–1.014, p = 0.005) and OS (HR 1.009, 95% CI
1.003–1.016, p = 0.004).
To illustrate the association between mutated KRAS
plasma concentration and survival, the patients were
split into three groups: (1) those with plasma concen-
trations of mutated KRAS above the median of 37.0
mutated copies/ml, (2) those with concentrations
below 37.0 mutated copies/ml, and (3) those without
detectable KRAS mutations. For the three groups, the
median PFS was 6.7 versus 16.1 versus 70.1 months,
respectively (p < 0.001), and the median OS was
6.7 months, 28.1 months, and not reached, respec-
tively (p = 0.002) (Figure 3).
Figure 2. Association between detectable KRAS mutation in plasma and PFS (A) and OS (B). NR, not reached.
Table 2. Associations between mutant KRAS plasma concentration, PFS, and OS.
PFS OS
HR 95% CI p HR 95% CI p
Age (years) 1.01 0.96–1.07 0.65 1.05 1.00–1.11 0.06
Sex Female 1 (ref )
Male 0.66 0.26–1.70 0.39 0.55 0.19–1.55 0.26
Clinical stage I 1 (ref) 1 (ref )
II 2.11 0.54–8.25 0.28 1.82 0.41–8.14 0.43
III 2.70 0.71–10.30 0.15 2.20 0.47–10.40 0.32
IV 2.18 0.22–21.94 0.51 3.58 0.28–45.46 0.33
WHO PS 0 1 (ref) 1 (ref)
1 0.72 0.30–1.73 0.47 0.84 0.33–2.10 0.70
2 4.45 0.74–26.68 0.10 8.31 1.24–55.62 0.03
Treatment intention Complete resection 1 (ref) 1 (ref)
Curative radiochemotherapy 1.02 0.18–5.72 0.99 0.61 0.06–6.02 0.68
Palliative chemotherapy and/or radiotherapy 9.76 1.55–61.49 0.02 5.48 0.86–34.79 0.07
Mutant KRAS concentration (mutated copies/ml plasma) 1.008 1.002–1.014 0.005 1.009 1.003–1.016 0.004
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Discussion
In summary, 23 (38%) of the 60 patients had detectable
KRAS mutation in their baseline plasma sample. There
was no difference in DNA yield across disease stages or
between patients with or without detectable KRAS muta-
tions in plasma. The fraction of patients with detectable
KRAS mutations and the concentration of mutated KRAS
increased with increasing disease stage. Patients with
detectable plasma KRAS mutations had significantly
worse PFS and OS than the patients with undetectable
mutations. There was also a negative association between
high concentrations of mutated KRAS and PFS and OS.
The increase in ctDNA concentration with increas-
ing disease stage is well known and is consistent with
the results of other studies [3,10,14]. In addition, the
fraction of patients with detectable KRAS mutations
across disease stages in our study is consistent with
other studies on NSCLC using ddPCR for the KRAS
analyses of plasma [21–23].
A negative association between detectable KRAS muta-
tions in baseline plasma and survival has been demon-
strated in studies on patients with pancreatic and colorectal
cancer [24–26]. Qualitative studies of patients with
NSCLC have also demonstrated an association between
detectable KRASmutations in serum or plasma at baseline
and worse PFS and/or OS [23,27–33]. A recent study,
where plasma was analysed for known genetic aberrations
in tumour DNA, also showed that detectable baseline
ctDNA was associated with shorter OS [34]. However, in
three other studies on the detection of KRAS mutations in
serum or plasma, no associations with survival were found
[35–37]. The results of two of these studies might be
explained by heterogeneity of the study populations (some
included non-adenocarcinoma patients), no prior analyses
of corresponding tumour DNA, and a limited number of
hot-spot KRAS mutations targeted in the ctDNA analyses
[35,36]. In the third study [37], only patients with
advanced KRAS mutated NSCLC were included, but the
proportion of patients with detectable KRAS mutation in
plasma was lower (48%) compared to the detection rate in
other, similar studies [21,22]. ctDNA studies of lung ade-
nocarcinoma patients harbouring mutations of the epider-
mal growth factor receptor (EGFR) gene have also shown
diverging results, but these might be explained by differ-
ences in treatment history [38–40].
Quantitative studies of ctDNA levels, assessing
either the concentration of ctDNA or the mutant allele
frequency (MAF), have shown a negative correlation
between high baseline ctDNA concentration and sur-
vival in colorectal cancer [10,41], pancreatic cancer
[13,42], breast cancer [11,43], oesophageal cancer [44],
and malignant melanoma [12,45]. While many studies
on NSCLC have shown a negative association between
the levels of cfDNA, as summarised in the meta-
analyses by Ai et al and Cargnin et al [46,47], few have
assessed the impact of mutant ctDNA levels before the
first treatment. Two recent studies have suggested that
Figure 3. Association between ctDNA concentration of mutated KRAS (copies/ml) and (A) PFS and (B) OS. NR, not reached; 37.0
copies/ml was the median concentration of mutated KRAS among those with detectable KRAS mutations in plasma.
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high MAFs of detected alterations are associated with
worse PFS and OS also in NSCLC [48,49].
Our work has some limitations. It is a retrospective
study with a limited number of patients, especially with
respect to patients with stages I and II disease. We detected
mutated KRAS in only a small proportion of the patients
with stages I and II disease, which may be explained by
the low MAF of ctDNA in early-stage disease [3,50].
More comprehensive NGS panels with capturing and
sequencing approaches optimised for ctDNA, such as Can-
cer Personalised Profiling by deep Sequencing (CAPP-
Seq) [15], Tracking Cancer Evolution Through Therapy
(TRACERx) [3,50], and Targeted Error Correction
Sequencing (TEC-Seq) [41], may increase the sensitivity
of ctDNA analyses, but detection of ctDNA in early-stage
disease remains a challenge.
As aforementioned, baseline cfDNA levels in
plasma or serum may have prognostic value [46,47]
and may also be used in disease monitoring [51]. We
did not conduct any additional analyses of cfDNA
beyond measuring the DNA yield from plasma prior
to ddPCR, although further analyses of the cfDNA
levels using reference genes as markers for cfDNA
would have been of interest. However, standardised
methods for analyses of cfDNA are needed [52,53].
Another potential limitation of our study is the range
of days between blood sample collection and commenc-
ing treatment (0–307 days). In four patients, the blood
samples were collected >90 days before treatment due to
intercurrent diseases or difficulties in obtaining tissue
specimens (patient IDs 30, 31, 52, and 57; see supple-
mentary material, Table S1). During the diagnostic work-
up, one of these patients had radiological progression
from stage IB to IIB, while there was no radiological pro-
gression in the other three patients. The results of the sur-
vival analyses were not altered when running sensitivity
analyses excluding these four patients (data not shown).
The storage time of the plasma samples may also be
a potential limitation. The amount of cfDNA in a
plasma sample may decrease during storage [54,55]
and could have an impact on the detection rate. We
did not, however, find any significant difference in the
total KRAS concentration between plasma samples
with different storage times (data not shown).
Using a single gene or few genes approach targeting
known tumour-specific mutations in ctDNA by ddPCR
has some advantages over NGS. It may minimise the
risk of falsely misinterpreting somatic mutations in
haematopoietic stem cells associated with clonal
haematopoiesis as tumour derived [56,57]. In addition,
for monitoring treatment and disease course, accurate
quantification of nucleic acids combined with simple
workflow, low cost, and less complex data analysis
make ddPCR a feasible technique in the daily routine
of a diagnostic laboratory.
Although the assays we used have been validated
by the manufacturer, we performed in-house valida-
tion with tests for linearity and establishment of
LODs for each assay. In our experience, comparing
detection rates of ctDNA across different studies is
challenging, even if the same platforms for ctDNA
analyses have been used. Data on false-positive rates
and how the LOD was determined is important infor-
mation that should be available for cross-study com-
parison. Lack of concordance between validated
commercial kits for KRAS mutation detection, which
have the same LOD according to the manufacturers,
has been reported [58]. Therefore, the false-positive
rate and LOD should be established in house for the
assays used, even if the assays are pre-validated by
the manufacturer.
In conclusion, patients with detectable KRAS muta-
tion in their baseline plasma sample had worse PFS
and OS than patients who did not have detectable
KRAS mutations. Our findings also suggest that the
baseline plasma concentration of mutated KRAS before
the first treatment may be an important, independent
prognostic factor in KRAS-positive lung adenocarci-
nomas. Hence, a quantitative analysis assessing the
plasma concentration of mutated KRAS improves the
prognostic value compared to qualitative analysis only.
These findings are confirmed in other studies, but the
value of ctDNA baseline levels in treatment decision-
making must be evaluated in larger prospective clini-
cal trials. Finally, ddPCR for ctDNA analyses is a
highly sensitive and accurate technique that can be
implemented in a daily diagnostic routine.
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